• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

    11/12/24 4:47:03 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMCR alert in real time by email
    SC 13G/A 1 rocksprings-imcr093024a4.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*



    Immunocore Holdings plc

    (Name of Issuer)

     

    Ordinary Share, nominal value £0.002 per share

    (Title of Class of Securities)

     

    45258D105**

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **This CUSIP number applies to the Issuer’s American Depositary Shares (“ADSs”). Each one ADS represents one Ordinary Share.  No CUSIP has been assigned to the Ordinary Shares.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  45258D105
     SCHEDULE 13G/A
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital Management LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    IA

     

     


     

    CUSIP No.  45258D105
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    OO; HC

     

     


     

    CUSIP No.  45258D105
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital Master Fund LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    PN

     

     
     

     

    CUSIP No.  45258D105
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Immunocore Holdings plc (the “Issuer”)

    (b) Address of Issuer’s Principal Executive Offices

    92 Park Drive

    Milton Park

    Abingdon, Oxfordshire OX14 4RY

    United Kingdom

    Item 2.(a) Name of Person Filing

    This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

    i. Rock Springs Capital Management LP (“RSCM”);

    ii. Rock Springs Capital LLC (“RSC”); and

    iii. Rock Springs Capital Master Fund LP (“Master Fund”).

    This Statement relates to Shares (as defined herein) held directly by the Master Fund, which is a Cayman Island exempted limited partnership, and indirectly held by RSCM, a Delaware limited partnership, and RSC, a Delaware limited liability company. RSCM serves as the investment manager to the Master Fund. RSC is the general partner of RSCM.

    (b) Address of Principal Business Office, or, if none, Residence

    Rock Springs Capital Management LP and Rock Springs Capital LLC

    650 South Exeter, Suite 1070

    Baltimore, MD 21202

     

    Rock Springs Capital Master Fund LP

    c/o Walkers Corporate Limited

    190 Elgin Avenue

    George Town, Grand Cayman, KY1-9008, Cayman Islands

     

    (c) Citizenship

    Rock Springs Capital Management LP - Delaware

    Rock Springs Capital LLC - Delaware

    Rock Springs Capital Master Fund LP - Cayman Islands

     (d) Title of Class of Securities

    Ordinary share, nominal value £0.002 per share (the “Shares”)

     (e) CUSIP No.:

    45258D105*

    * This CUSIP number applies to the Issuer’s American Depositary Shares (“ADSs”). Each one ADS represents one Ordinary Share.  No CUSIP has been assigned to the Ordinary Shares.

     
     

     

    CUSIP No.  45258D105
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not Applicable.

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

     
     

     

    CUSIP No. 45258D105
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    As of September 30, 2024, each of RSC and RSCM may be deemed to be the beneficial owners of 0 Shares, which amount includes 0 ADS, each one representing one Share, directly beneficially owned by the Master Fund.

    (a) Amount beneficially owned:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    (b) Percent of class:

    Rock Springs Capital Management LP: 0%

    Rock Springs Capital LLC: 0%

    Rock Springs Capital Master Fund LP: 0%

     

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    (ii) Shared power to vote or to direct the vote:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    (iii) Sole power to dispose or to direct the disposition of:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    (iv) Shared power to dispose or to direct the disposition of:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    See disclosure in Items 2 and 4 hereof. Certain funds listed in Item 2(a) are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Persons.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Please see response to Item 2.

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     
     
    CUSIP No.  45258D105
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 12, 2024

     

     

     

    Rock Springs Capital Management LP

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

      Rock Springs Capital LLC
           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

      Rock Springs Capital Master Fund LP
     

    By: Rock Springs Capital Management LP, Investment Manager

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

     

     
     
    CUSIP No.  45258D105
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

     

    JOINT FILING AGREEMENT

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Date: November 12, 2024

     

     

     

    Rock Springs Capital Management LP

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

      Rock Springs Capital LLC
           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

      Rock Springs Capital Master Fund LP
     

    By: Rock Springs Capital Management LP, Investment Manager

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

     

     

     

     

     

     

    Get the next $IMCR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMCR

    DatePrice TargetRatingAnalyst
    3/16/2026$33.00Buy → Hold
    Jefferies
    1/7/2026$55.00Sell → Buy
    UBS
    10/31/2025$60.00Overweight
    Wells Fargo
    9/18/2025Neutral
    Guggenheim
    8/25/2025$48.00Buy
    Jefferies
    5/27/2025$65.00Buy
    Deutsche Bank
    12/13/2024$74.00 → $35.00Overweight → Equal-Weight
    Morgan Stanley
    11/11/2024$72.00 → $38.00Outperform → Neutral
    Mizuho
    More analyst ratings

    $IMCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Coy Travis Alan

    4 - Immunocore Holdings plc (0001671927) (Issuer)

    2/19/26 5:00:28 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF HR OFFICER St Leger Tina Amber converted options into 2,119 units of Ordinary Shares and sold $32,350 worth of Ordinary Shares (1,000 units at $32.35) (SEC Form 4)

    4 - Immunocore Holdings plc (0001671927) (Issuer)

    2/19/26 5:00:15 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP, FINANCE & CAO Goll John converted options into 1,351 units of Ordinary Shares and sold $22,580 worth of Ordinary Shares (698 units at $32.35) (SEC Form 4)

    4 - Immunocore Holdings plc (0001671927) (Issuer)

    2/19/26 5:00:17 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baker Bros. Advisors Lp bought $23,993,224 worth of American Depositary Shares (807,338 units at $29.72) (SEC Form 4)

    4 - Immunocore Holdings plc (0001671927) (Issuer)

    3/19/25 6:40:21 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Immunocore downgraded by Jefferies with a new price target

    Jefferies downgraded Immunocore from Buy to Hold and set a new price target of $33.00

    3/16/26 8:35:28 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunocore upgraded by UBS with a new price target

    UBS upgraded Immunocore from Sell to Buy and set a new price target of $55.00

    1/7/26 8:39:16 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wells Fargo initiated coverage on Immunocore with a new price target

    Wells Fargo initiated coverage of Immunocore with a rating of Overweight and set a new price target of $60.00

    10/31/25 8:20:02 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

    Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 17 March 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will present the five-year overall survival (OS) from the KIMMTRAK (tebentafusp-tebn) Phase 3 trial in previously untreated HLA-A*02:01 positive patients with unresected or metastatic uveal melano

    3/17/26 4:30:00 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types

    Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 5, 2026 /CNW/ -- Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress in early detection, targeted therapy, and immunotherapy[1]. Yet cancer remains the second-leading cause of death worldwide, with an estimated 2.1 million new diagnoses expected in 2026 alone and mortality rates still climbing among younger populations[2]. Companies delivering next-generation oncology treatments across multiple tumor types include Oncolytics Biotech (NASDAQ:ONCY), Vir Biotechnology (NASDAQ:VIR), Iovance Biotherapeutics (NASDAQ:IOVA), C4 Therapeutic

    3/5/26 9:00:00 AM ET
    $CCCC
    $IMCR
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Immunocore to present at upcoming investor conferences

    Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 03 March 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in March.         TD Cowen 46th Annual Healthcare Conference         Presentation: Tuesday, March 3, 2026, at 2:30 p.m. EST         Leerink 2026 Global Healthcare Conference         Fireside Chat: Monday, March

    3/3/26 7:00:00 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMCR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Immunocore Holdings plc

    SCHEDULE 13G/A - Immunocore Holdings plc (0001671927) (Subject)

    3/6/26 12:57:46 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunocore Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Immunocore Holdings plc (0001671927) (Filer)

    2/25/26 7:30:36 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Immunocore Holdings plc

    10-K - Immunocore Holdings plc (0001671927) (Filer)

    2/25/26 7:01:19 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMCR
    Financials

    Live finance-specific insights

    View All

    Immunocore reports fourth quarter and full year 2025 financial results and provides a business update

    Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; expect moderating revenue growth in 2026 TEBE-AM enrollment completion anticipated 1H 2026 with topline data expected as early as 2H 2026 PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp in ovarian and lung cancer, and initial data with half-life extended candidate (IMC-P115C) Additional Phase 1 HIV data to be presented in 2H 2026 Cash, cash equivalents and marketable securities of $864.2 million as of December 31, 2025 Conference call today, February 25 at 8:00AM ET

    2/25/26 7:00:00 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025

    Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 18 February 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Wednesday, February 25, 2026. Following the announcement, the Company will host a live teleconference and webcast a

    2/18/26 7:00:00 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immunocore reports second quarter financial results and provides a business update

    KIMMTRAK® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 Dose selection for PRISM-MEL-301 Phase 3 trial expected in 2H 2025 Phase 1 single ascending dose HBV data for IMC-I109V will be presented at the 2025 AASLD Liver Meeting Cash, cash equivalents and marketable securities of $883 million as of June 30, 2025 Conference call today, August 7 at 8:00 AM ET, 1:00 PM BST (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, August 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and de

    8/7/25 7:00:00 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMCR
    Leadership Updates

    Live Leadership Updates

    View All

    Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

    Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that Travis Coy has been appointed as Executive Vice President (EVP), Chief Financial Officer and Head of Corporate Development, effective January 1, 2025. He will become an Exe

    1/2/25 7:00:00 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Levicept Appoints Eliot Forster as CEO

    Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

    11/30/23 4:00:00 AM ET
    $IMCR
    $IMTX
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Immunocore Appoints Siddharth Kaul to its Board of Directors

    Immunocore Appoints Siddharth Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announces the appointment of Siddharth (Sid) Kaul as a non-Executive member of its Board of Directors, effective June 8, 2022. Sid will serve as a Class II director and also serve as a member of the Audit and Remuneration committees. Sid is a s

    6/9/22 7:45:00 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

    SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

    11/14/24 1:28:34 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

    SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

    11/14/24 1:22:39 PM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

    SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

    11/14/24 6:40:08 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care